Literature DB >> 8323396

Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon.

C S Lau1, M McLaren, I Mackay, J J Belch.   

Abstract

OBJECTIVES: (1) To assess if patients with various forms of Raynaud's phenomenon (RP) have abnormal plasma fibrinolysis that may contribute to diminished digital blood flow; (2) to assess whether patients with RP with evidence of endothelial damage have abnormal plasma fibrinolysis; (3) to determine the clinical relevance of abnormalities, if any, in plasma fibrinolysis in patients with RP.
METHODS: One hundred and sixty eight patients with significant RP were studied--46 had primary Raynaud's disease (RD), 32 had suspected Raynaud's syndrome secondary to an undifferentiated connective tissue disorder (undifferentiated CTD), 25 had Raynaud's syndrome associated with atherosclerosis (athero RS), and 65 had an underlying connective tissue disease (CTD RS). All attended in the morning after a low fat light breakfast. After a clinical history was obtained, venous blood samples were collected without stasis for assays of plasma fibrinolysis and factor VIII von Willebrand factor antigen (fVIII vWF Ag). Results were compared with those obtained from normal subjects matched for sex and age. As patients with athero RS were significantly older than the other patients with Raynaud's phenomenon, two groups of control subjects were recruited--namely, 'old' and 'young' control subjects.
RESULTS: Patients with CTD RS and athero RS had higher concentrations of fVIII vWF Ag (CTD RS median 174.5 range (45-370)% v 100 (38-202)%, p < 0.001; athero RS 182-5 (100-240)% v 100 (50-158)%, p < 0.001). Both had raised fibrinogen (CTD RS 3.25 (1.9-6.8) g/l v 2.4 (1.2-4.2) g/l, p < 0.001; athero RS 3.4 (2.2-6.2) g/l v 2.5 (1.8-3.9) g/l, p < 0.001) and both had diminished fibrinolysis with reduced plasminogen activator activity (CTD RS 79.5 (31-72) mm2 v 92 (37-197) mm2, p < 0.04; athero RS 73 (45-125) mm2 v 98 (41-197) mm2, p < 0.03). Patients with CTD RS also had raised plasminogen activity (3.3 (2.3-5.8) cU/ml v 2.9 (1.5-5.4) cU/ml, p < 0.001). On the contrary, patients with primary RD and undifferentiated CTD had normal fibrinogen and plasma fibrinolysis. Within each patient group, no significant differences in any of the measured variables were found between those who had RP all year and those who had RP in the winter only, those with RP of the hands only and of hands and feet, or those with and without digital ulcers.
CONCLUSION: Diminished plasma fibrinolysis is found in patients likely to have endothelial damage (CTD RS and athero RS). These changes are probably a consequence rather than a cause of the disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8323396      PMCID: PMC1005069          DOI: 10.1136/ard.52.6.443

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

1.  BLOOD VISCOSITY AND RAYNAUD'S DISEASE.

Authors:  R PRINGLE; D N WALDER; J P WEAVER
Journal:  Lancet       Date:  1965-05-22       Impact factor: 79.321

2.  Vascular damage and factor-VIII-related antigen in the rheumatic diseases.

Authors:  J J Belch; A A Zoma; I M Richards; K McLaughlin; C D Forbes; R D Sturrock
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

3.  Blood fibrinolytic activity in diseases of small blood vessels and the effect of low molecular weight dextran.

Authors:  W J Cunliffe; I S Menon
Journal:  Br J Dermatol       Date:  1969-03       Impact factor: 9.302

4.  The extrinsic fibrinolytic system in survivors of myocardial infarction.

Authors:  T K Nilsson; O Johnson
Journal:  Thromb Res       Date:  1987-12-15       Impact factor: 3.944

5.  Tissue plasminogen activator: chemical and physiological aspects.

Authors:  F Bachmann; I E Kruithof
Journal:  Semin Thromb Hemost       Date:  1984-01       Impact factor: 4.180

6.  Abnormal blood viscosity in Raynaud's phenomenon.

Authors:  K B Goyle; J A Dormandy
Journal:  Lancet       Date:  1976-06-19       Impact factor: 79.321

7.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

9.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

10.  Treatment of Raynaud's phenomenon by fibrinolytic enhancement.

Authors:  P E Jarrett; M Morland; N L Browse
Journal:  Br Med J       Date:  1978-08-19
View more
  4 in total

1.  Association of von Willebrand factor and fibrinogen plasma levels with primary Raynaud's phenomenon in male and female patients.

Authors:  Alajos-Tamas Takáts; Amir-Houshang Shemirani; Katalin-Szilvia Zsóri; Csilla András; Zoltán Csiki
Journal:  Rheumatol Int       Date:  2011-11-16       Impact factor: 2.631

2.  Macrovascular disease and systemic sclerosis.

Authors:  M Ho; D Veale; C Eastmond; G Nuki; J Belch
Journal:  Ann Rheum Dis       Date:  2000-01       Impact factor: 19.103

3.  Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.

Authors:  A L Herrick; K Illingworth; A Blann; C R Hay; S Hollis; M I Jayson
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

Review 4.  Raynaud's phenomenon: new aspects of pathogenesis and the role of nailfold videocapillaroscopy.

Authors:  Anna Kuryliszyn-Moskal; Jacek Kita; Anna Hryniewicz
Journal:  Reumatologia       Date:  2015-05-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.